These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 21254864)

  • 1. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
    Giorgi MA; Cohen Arazi H; Gonzalez CD; Di Girolamo G
    Expert Opin Pharmacother; 2011 Jun; 12(8):1285-95. PubMed ID: 21254864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive comparative review of adenosine diphosphate receptor antagonists.
    Oh EY; Abraham T; Saad N; Rapp JH; Vastey FL; Balmir E
    Expert Opin Pharmacother; 2012 Feb; 13(2):175-91. PubMed ID: 22216937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
    Oprea AD; Popescu WM
    J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of phenotypic and genetic testing in managing clopidogrel therapy.
    Chan NC; Eikelboom JW; Ginsberg JS; Lauw MN; Vanassche T; Weitz JI; Hirsh J
    Blood; 2014 Jul; 124(5):689-99. PubMed ID: 24951432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
    Roffman DS
    J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
    Torngren K; Ohman J; Salmi H; Larsson J; Erlinge D
    Cardiology; 2013; 124(4):252-8. PubMed ID: 23594617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Kern MJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555
    [No Abstract]   [Full Text] [Related]  

  • 14. Prasugrel hydrochloride for the treatment of acute coronary syndromes.
    Lhermusier T; Waksman R
    Expert Opin Pharmacother; 2015 Mar; 16(4):585-96. PubMed ID: 25633751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
    Serebruany VL; DiNicolantonio JJ
    Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2Y12 inhibitors in acute coronary syndromes: which and when?
    Pais P
    Natl Med J India; 2013; 26(2):84-90. PubMed ID: 24093982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
    Piccolo R; Di Gioia G; Niglio T; D'Anna C; De Rosa R; Strisciuglio T; Bevilacqua M; Piscione F; Cirillo P; Galasso G
    Angiology; 2014 Feb; 65(2):130-6. PubMed ID: 23221279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
    Golino P
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute coronary syndromes: identifying the appropriate patient for prasugrel.
    Stephens JC; Askari AT
    Postgrad Med; 2012 Mar; 124(2):16-28. PubMed ID: 22437212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.